|
|
Upfront Briefing
So much for the stock-pickers running the show. May CPI printed 4.2% — the hottest in three years, courtesy of an Iran-driven jump at the pump — and sent the rate crowd into a crouch ahead of next week's FOMC, torching anything growth-sensitive. Biotech got no hall pass: XBI and NBI each shed ~1.9%, roughly in line with a Nasdaq down 2%, proving that on a macro day even the good stuff gets sold with everything else.
And there was good stuff to sell. Roche bagged a Tecentriq review clock in colon cancer, J&J dropped pivotal data on the first drug that could ever be approved for warm autoimmune hemolytic anemia, and Parabilis' record IPO ripped 58% on a day the tape bled — proof the window's wide open. Humacyte, meanwhile, ran the oldest play in the book: post a Phase 3 win at breakfast, pass the hat for $50M before the champagne went flat.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,267.0 |
(1.6%) |
5.9% |
| Nasdaq 100 |
28,508.0 |
(2.0%) |
13.1% |
| Russell 2000 |
2,835.5 |
(1.1%) |
13.0% |
| Healthcare (XLV) |
152.9 |
(1.1%) |
(1.7%) |
| Biotech (XBI) |
128.9 |
(1.9%) |
6.0% |
| Nasdaq Biotech (NBI) |
5,763.7 |
(1.9%) |
1.0% |
| Clinical Trials (BBC) |
40.7 |
(1.8%) |
8.1% |
|
- Biotech got no safe harbor: XBI and NBI both fell ~1.9% alongside a Nasdaq down 2%, and the day's real wins — Humacyte's Phase 3 dialysis readout, Roche's Tecentriq review date, and J&J's first-in-disease wAIHA data — couldn't pull the group green.
- This was a macro job: May CPI ran 4.2% YoY — a three-year high — on a 23.5% annual energy spike as the Iran conflict bid crude, hardening bets the Fed stays parked at the 17 June FOMC and hammering rate-sensitive growth and tech.
- Market data: U.S. cash close Wednesday, 10 June 2026.
The Big 3
|
1
|
FDA grants Priority Review for Roche's Tecentriq in colon
|
-
The FDA accepted Roche's sBLA and granted Priority Review for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision due 9 October 2026.
-
Why it matters: Priority Review hands Roche a dated 9 October catalyst and a credible path into adjuvant dMMR/MSI-H colon cancer, a curative-intent setting worth far more than late-line. The case rests on ATOMIC, where atezolizumab plus FOLFOX cut recurrence or death by roughly half and pushed three-year disease-free survival to 86% from 76%. Land it and Roche plants a PD-(L)1 in early colon cancer ahead of Merck and BMS, still working Keytruda and Opdivo in the neoadjuvant setting, and adds ballast to a franchise leaking ground to biosimilars. The catch: overall survival wasn't significant at the cutoff, so the durability debate rides into October with it.
- Source: PR
|
|
2
|
J&J's IMAAVY posts pivotal wAIHA data, lining up a first-in-disease approval
|
-
Full ENERGY Phase 2/3 results showed nipocalimab drove a durable hemoglobin response over placebo (>10 g/dL, sustained) in warm autoimmune hemolytic anemia, with improvement as early as Week 1 and a fatigue benefit, in a disease with no approved therapies; the sBLA already holds FDA Priority Review.
-
Why it matters: The full readout turns a pending sBLA into a real launch: clearing the durable-response bar with a fatigue signal payers actually price gives J&J a clean shot at the first-ever wAIHA approval on a ~H2 2026 clock. The read-through runs to the whole FcRn class — it widens nipocalimab's autoimmune footprint beyond gMG and keeps the pressure on Argenx to push Vyvgart's label rather than cede rare hematology. A roughly 1-in-8,000 population caps the dollar size, but first mover in an empty indication tends to get rewarded well ahead of the numbers.
-
Source:
PR
-
More:
BioSpace
|
|
3
|
Parabilis closes its debut up 58%, bucking a red tape
|
-
A day after pricing the largest biotech IPO ever ($670M at $20), Parabilis (PBLS) opened +67% and closed its Nasdaq debut at $31.60 — up ~58% — lifting its market cap to roughly $3.8B even as the broad tape fell ~2%.
-
Why it matters: The pricing was yesterday's story; the tape is today's. A record raise that then trades up 58% — on a session where the Nasdaq dropped 2% and biotech fell with it — is the cleanest "risk appetite is back" signal the group has had in two years, and bankers sitting on filed-but-paused S-1s just got their comp. The catch is the one every day-one moonshot carries: a ~$3.8B cap on a Phase 3-bound Wnt/β-catenin asset with no revenue prices in a lot, and debut pops have a habit of bleeding back once the float finds its level.
-
Source:
Endpoints
-
More:
BioPharma Dive
|
Everything Else that broke
-
EHA 2026 opened in Stockholm (June 11–14), with the desk watching Legend Biotech's (LEGN) first-in-human in vivo CD19/CD20 CAR-T LB2501 (late-breaker; 100% ORR and 83% CR in the dose-level-2 cohort, no lymphodepletion) and Disc Medicine's (IRON) RALLY-MF readout for DISC-0974 in myelofibrosis anemia (70% overall response).
- Sanofi stopped a Phase 3 trial of complement C1s blocker riliprubart in CIDP early after an interim review found it unlikely to deliver enough efficacy — another pipeline dent, and a read-through for Argenx's Vyvgart (already approved in CIDP) and Dianthus' (DNTH) C1 inhibitor claseprubart still in Phase 3. — Fierce Biotech
- Novartis said delpacibart braxlosiran met the primary biomarker endpoint in a Phase I/II FSHD study. — PR
- Genentech is closing its infectious disease unit in another round of early R&D layoffs. — Endpoints
- Elixiron reported positive Phase 2 interim Alzheimer's data for enrupatinib, citing early cognitive benefit. — PR
- GlycoNex said Phase III denosumab biosimilar SPD8 met its primary endpoint. — PR
- Tectonic completed enrollment in the 24-week Phase 2 TX45 APEX study in PH-HFpEF. — PR
- CStone highlighted ASCO data for CS2009, its PD-1/VEGF/CTLA-4 trispecific antibody. — PR
- Roche's VENTANA MMR RxDx Panel won IVDR approval across multiple cancer types and therapies. — PR
- Exicure received a Nasdaq notice tied to minimum stockholders' equity requirements. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Teva closed the Emalex acquisition, adding ecopipam with a U.S. NDA planned in 2H 2026. — PR
- Novartis struck a second Orionis deal, $40M upfront and up to $1.4B in milestones, to pursue molecular-glue programs against challenging targets. — Fierce Biotech
VC / Private Financings
- SonoThera closed an oversubscribed $125M Series B for ultrasound-and-microbubble nonviral gene delivery, led by Vida Ventures with the venture arms of UCB, Bayer, Otsuka and J&J; proceeds fund clinical starts in DMD (full-length dystrophin) and ADPKD. — Fierce Biotech
- Beren raised $300M ahead of a fall FDA decision — $135M in equity alongside a $165M (non-dilutive) debt facility. — Endpoints
- Ethyreal launched with $101M across Series A and B to target Graves' disease and thyroid eye disease, backed by Atlas Venture and Medicxi Ventures. — Fierce Biotech
IPOs / Follow-Ons
- Parabilis (PBLS) priced a record $670M Nasdaq IPO at $20 — the largest in biotech history — plus a $75M Regeneron placement. — Fierce Biotech
- VERAXA closed its SPAC combination with Voyager and begins Nasdaq trading as VRXA on June 11. — PR
- Humacyte (HUMA) priced a $50M follow-on at $1.05 (see Everything Else). — PR
Academic Corner
- Dual-target gene therapy BBM-P002 was safe and well tolerated in Parkinson's disease, with 12-month motor improvements in a multicenter phase 1 trial. — Nature Medicine
- Hospital tranexamic acid policy cut red-cell transfusions in major noncardiac surgery, with venous thromboembolism rates unchanged at 90 days. — NEJM
- Cell detailed an extracellular allosteric gate that modulates GPR119 ligand efficacy in a new cryo-EM structure study. — Cell
|
Keep your powder dry — green tomorrow, probably. — BioBucks Team
|
|
|
